AtriCure, Inc. (ATRC)

Data as of Sep 24, 2026, from SEC Form 4 filings.

XNASSURGICAL & MEDICAL INSTRUMENTS & APPARATUSNet insider selling (90d)Watch ATRC

See up to 3 months of ATRC. The 7-day demo opens the 1M and 3M ranges and puts ATRC on your watchlist.

Latest ATRC insider trades

Salvatore Privitera - Officer
Open-market sale$271K
Sep 23, 2026
Regina E. Groves - Director
Open-market sale

About AtriCure, Inc. (ATRC)

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Headquarters: MASON, OH
Employees: 1,350
Listed: 2005
Exchange: XNAS
Sector: Health Care

https://www.atricure.com SEC filings for ATRC on EDGAR

ATRC Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market sale	10	74,868	$3.32M
Option exercise	2	50,000
Bona-fide gift	2	4,700

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

ATRC insider transactions (Form 4)

54 Form 4 filings on record, the earliest from Dec 12, 2024, newest first. Filing history page 1 of 2.

Date	Insider	Transaction	Security	Shares	Price	Value
Sep 23, 2026	Salvatore Privitera - Officer	Open-market sale	Common Stock	4,519^{footnote F1}	$60.00	$271K
Footnote F1 (shares): These shares were sold pursuant to a 10b5-1 trading plan adopted on February 20, 2026
Sep 11, 2026	Regina E. Groves - Director	Open-market sale	Common Stock	5,313	$54.22^{footnote F1}	$288K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $54.09 to $54.38 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
Sep 8, 2026	Salvatore Privitera - Officer	Open-market sale	Common Stock	3,657^{footnote F1}	$55.00	$201K
Footnote F1 (shares): These shares were sold pursuant to a 10b5-1 trading plan adopted on February, 20, 2026.
Sep 2, 2026	Salvatore Privitera - Officer	Open-market sale	Common Stock	7,763^{footnote F1}	$52.50	$408K
Footnote F1 (shares): These shares were sold pursuant to a 10b5-1 trading plan adopted on February 20, 2026.
Aug 24, 2026	Karl S. Dahlquist - Officer	Open-market sale	Common Stock	9,370	$48.89^{footnote F1}	$458K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $48.88 to $48.89 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
Aug 5, 2026	Karen Prange - Director	Open-market sale	Common Stock	3,564	$38.80	$138K
Aug 5, 2026	Maggie Yuen - Director	Open-market sale	Common Stock	3,500	$38.42^{footnote F1}	$134K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $38.37 to $38.43 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
Jul 30, 2026	Michael H. Carrel - Officer	Gift	Common Stock	700	$0.00^{footnote F1}	-
Jul 30, 2026	Michael H. Carrel - Officer	Gift	Common Stock	4,000	$0.00^{footnote F2}	-
Footnote F1 (price): No consideration was received in connection with this gift to the reporting person's parent. Footnote F2 (price): No consideration was received in connection with this charitable gift.
Jul 28, 2026	Vinayak Doraiswamy - Officer	Open-market sale	Common Stock	6,000	$38.88^{footnote F1}	$233K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
Jul 28, 2026	Sven Wehrwein - Director	Option exercise	Common Stock	25,000	$19.95	$499K
Jul 28, 2026	Sven Wehrwein - Director	Open-market sale	Common Stock	25,000	$37.84^{footnote F1}	$946K
Jul 28, 2026	Sven Wehrwein - Director	Option exercise	Non-qualified Stock Option (right to buy)	25,000	$0.00	-
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $37.73 to $39.04 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
Jul 29, 2026	Justin J. Noznesky - Officer	Open-market sale	Common Stock	6,182	$38.80^{footnote F1}	$240K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $38.62 to $39.28 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
Jun 30, 2026	Michael H. Carrel - Officer	Grant or award	Common Stock	636^{footnote F1}	$23.78^{footnote F2}	$15K
Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.
Jun 30, 2026	Vinayak Doraiswamy - Officer	Grant or award	Common Stock	636^{footnote F1}	$23.78^{footnote F2}	$15K
Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.
Jun 30, 2026	Karl S. Dahlquist - Officer	Grant or award	Common Stock	636^{footnote F1}	$23.78^{footnote F2}	$15K
Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.
Jun 30, 2026	Douglas J. Seith - Officer	Grant or award	Common Stock	527^{footnote F1}	$23.78^{footnote F2}	$13K
Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.
Jun 30, 2026	Salvatore Privitera - Officer	Grant or award	Common Stock	636^{footnote F1}	$23.78^{footnote F2}	$15K
Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.
May 20, 2026	Karen Prange - Director	Open-market sale	Common Stock	3,000	$28.65^{footnote F1}	$86K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $28.60 to $28.76 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
May 18, 2026	Karen Prange - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 18, 2026	Deborah H. Telman - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 18, 2026	Maggie Yuen - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 18, 2026	Shlomo Nachman - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 18, 2026	B. Kristine Johnson - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 18, 2026	Regina E. Groves - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 18, 2026	Sven Wehrwein - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 18, 2026	Robert S. White - Director	Grant or award	Common Stock	6,144^{footnote F1}	$0.00	-
Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
May 15, 2026	Vinayak Doraiswamy - Officer	Open-market sale	Common Stock	5,000	$28.13	$141K
Mar 12, 2026	Vinayak Doraiswamy - Officer	Open-market sale	Common Stock	5,000	$29.83^{footnote F1}	$149K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $29.79 to $29.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR
Mar 10, 2026	Robert S. White - Director	Option exercise	Common Stock	10,000	$14.99	$150K
Mar 10, 2026	Robert S. White - Director	Option exercise	Non-qualified Stock Option (right to buy)	10,000	$14.99	$150K
Mar 6, 2026	Michael H. Carrel - Officer	Gift	Common Stock	5,000	$0.00^{footnote F1}	-
Mar 6, 2026	Michael H. Carrel - Officer	Gift	Common Stock	1,000	$0.00^{footnote F2}	-
Footnote F1 (price): No consideration was received in connection with this gift to the reporting person's children. Footnote F2 (price): No consideration was received in conjunction with this gift to the reporting person's sibling.
Mar 1, 2026	Michael H. Carrel - Officer	Grant or award	Common Stock	101,280	$0.00^{footnote F2}	-
Mar 1, 2026	Michael H. Carrel - Officer	Tax withholding / forfeiture	Common Stock	72,777^{footnote F3}	$31.26	$2.28M
Mar 1, 2026	Michael H. Carrel - Officer	Grant or award	Common Stock	68,618	$0.00^{footnote F1}	-
Footnote F1 (price): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Footnote F2 (price): The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. Footnote F3 (shares): The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Recent ATRC Form 8-K filings

Read ATRC company news

Jul 23, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

May 19, 2026Item 5.02, 5.07, 9.01

Read the filing on SEC EDGAR

May 6, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

May 5, 2026Item 2.02, 9.01

Recent ATRC Form 144 notices of proposed sale

An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.

Filed	Filer	Relationship	Shares	Market value	Notice
Sep 23, 2026	SALVATORE PRIVITERA	Officer	4,519	$271K	View on EDGAR
Sep 11, 2026	GROVES REGINA E	Director	5,313	$285K

Congress trades in ATRC

All congress trades

Stock trades in ATRC disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.

Member	Type	Traded	Disclosed	Value range	Owner	Days to disclose	Filing
Gilbert Ray Cisneros, Jr.Democrat, CA-31	Sale (partial)

ATRC insider trading FAQ

What is the latest insider trade for ATRC?

AtriCure, Inc. (ATRC) had 11 insider filings in the last 90 days, with the most recent on 2026-09-24. The full record for ATRC runs to 54 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying ATRC stock?

No insider purchases of ATRC were filed in the last 90 days.

How many insiders are selling ATRC stock?

10 insider sales of ATRC were filed in the last 90 days, totaling $3.32M.

Where can I see ATRC SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects ATRC Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Sep 24, 2026 - Salvatore Privitera view on EDGAR
Sep 14, 2026 - Regina E. Groves view on EDGAR
Sep 10, 2026 - Salvatore Privitera view on EDGAR
Sep 4, 2026 - Salvatore Privitera view on EDGAR
Aug 26, 2026 - Karl S. Dahlquist view on EDGAR
Aug 7, 2026 - Karen Prange view on EDGAR
Aug 7, 2026 - Maggie Yuen view on EDGAR
Aug 3, 2026 - Michael H. Carrel view on EDGAR
Jul 30, 2026 - Vinayak Doraiswamy view on EDGAR

Related companies with recent insider activity

Learn more

Insider selling: signal or noise?: Why most insider sales are routine, and the few patterns worth a second look.
Form 144 vs Form 4: A Form 144 announces a planned sale; the Form 4 reports it after it happens.
Insider activity in Health Care: Where ATRC's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow ATRC with a 7-day demo

ATRC on your watchlist
Every ATRC Form 4 filing on record
Up to 3 months of ATRC price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market sale

74,868

$3.32M

Option exercise

50,000

Bona-fide gift

4,700

Date

Insider

Transaction

Security

Price

Value

Sep 23, 2026

Salvatore Privitera - Officer

Open-market sale

Common Stock

4,519^{footnote F1}

$60.00

$271K

Footnote F1 (shares): These shares were sold pursuant to a 10b5-1 trading plan adopted on February 20, 2026

Sep 11, 2026

Regina E. Groves - Director

Open-market sale

Common Stock

5,313

$54.22^{footnote F1}

$288K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $54.09 to $54.38 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

Sep 8, 2026

Salvatore Privitera - Officer

Open-market sale

Common Stock

3,657^{footnote F1}

$55.00

$201K

Footnote F1 (shares): These shares were sold pursuant to a 10b5-1 trading plan adopted on February, 20, 2026.

Sep 2, 2026

Salvatore Privitera - Officer

Open-market sale

Common Stock

7,763^{footnote F1}

$52.50

$408K

Footnote F1 (shares): These shares were sold pursuant to a 10b5-1 trading plan adopted on February 20, 2026.

Aug 24, 2026

Karl S. Dahlquist - Officer

Open-market sale

Common Stock

9,370

$48.89^{footnote F1}

$458K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $48.88 to $48.89 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

Aug 5, 2026

Karen Prange - Director

Open-market sale

Common Stock

3,564

$38.80

$138K

Aug 5, 2026

Maggie Yuen - Director

Open-market sale

Common Stock

3,500

$38.42^{footnote F1}

$134K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $38.37 to $38.43 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

Jul 30, 2026

Michael H. Carrel - Officer

Gift

Common Stock

700

$0.00^{footnote F1}

Jul 30, 2026

Michael H. Carrel - Officer

Gift

Common Stock

4,000

$0.00^{footnote F2}

Footnote F1 (price): No consideration was received in connection with this gift to the reporting person's parent.
Footnote F2 (price): No consideration was received in connection with this charitable gift.

Jul 28, 2026

Vinayak Doraiswamy - Officer

Open-market sale

Common Stock

6,000

$38.88^{footnote F1}

$233K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

Jul 28, 2026

Sven Wehrwein - Director

Option exercise

Common Stock

25,000

$19.95

$499K

Jul 28, 2026

Sven Wehrwein - Director

Open-market sale

Common Stock

25,000

$37.84^{footnote F1}

$946K

Jul 28, 2026

Sven Wehrwein - Director

Option exercise

Non-qualified Stock Option (right to buy)

25,000

$0.00

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $37.73 to $39.04 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

Jul 29, 2026

Justin J. Noznesky - Officer

Open-market sale

Common Stock

6,182

$38.80^{footnote F1}

$240K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $38.62 to $39.28 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

Jun 30, 2026

Michael H. Carrel - Officer

Grant or award

Common Stock

636^{footnote F1}

$23.78^{footnote F2}

$15K

Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

Jun 30, 2026

Vinayak Doraiswamy - Officer

Grant or award

Common Stock

636^{footnote F1}

$23.78^{footnote F2}

$15K

Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

Jun 30, 2026

Karl S. Dahlquist - Officer

Grant or award

Common Stock

636^{footnote F1}

$23.78^{footnote F2}

$15K

Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

Jun 30, 2026

Douglas J. Seith - Officer

Grant or award

Common Stock

527^{footnote F1}

$23.78^{footnote F2}

$13K

Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

Jun 30, 2026

Salvatore Privitera - Officer

Grant or award

Common Stock

636^{footnote F1}

$23.78^{footnote F2}

$15K

Footnote F1 (shares): Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
Footnote F2 (price): In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

May 20, 2026

Karen Prange - Director

Open-market sale

Common Stock

3,000

$28.65^{footnote F1}

$86K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $28.60 to $28.76 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

May 18, 2026

Karen Prange - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 18, 2026

Deborah H. Telman - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 18, 2026

Maggie Yuen - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 18, 2026

Shlomo Nachman - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 18, 2026

B. Kristine Johnson - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 18, 2026

Regina E. Groves - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 18, 2026

Sven Wehrwein - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 18, 2026

Robert S. White - Director

Grant or award

Common Stock

6,144^{footnote F1}

$0.00

Footnote F1 (shares): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

May 15, 2026

Vinayak Doraiswamy - Officer

Open-market sale

Common Stock

5,000

$28.13

$141K

Mar 12, 2026

Vinayak Doraiswamy - Officer

Open-market sale

Common Stock

5,000

$29.83^{footnote F1}

$149K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $29.79 to $29.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security… Full note on SEC EDGAR

Mar 10, 2026

Robert S. White - Director

Option exercise

Common Stock

10,000

$14.99

$150K

Mar 10, 2026

Robert S. White - Director

Option exercise

Non-qualified Stock Option (right to buy)

10,000

$14.99

$150K

Mar 6, 2026

Michael H. Carrel - Officer

Gift

Common Stock

5,000

$0.00^{footnote F1}

Mar 6, 2026

Michael H. Carrel - Officer

Gift

Common Stock

1,000

$0.00^{footnote F2}

Footnote F1 (price): No consideration was received in connection with this gift to the reporting person's children.
Footnote F2 (price): No consideration was received in conjunction with this gift to the reporting person's sibling.

Mar 1, 2026

Michael H. Carrel - Officer

Grant or award

Common Stock

101,280

$0.00^{footnote F2}

Mar 1, 2026

Michael H. Carrel - Officer

Tax withholding / forfeiture

Common Stock

72,777^{footnote F3}

$31.26

$2.28M

Mar 1, 2026

Michael H. Carrel - Officer

Grant or award

Common Stock

68,618

$0.00^{footnote F1}

Footnote F1 (price): The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.
Footnote F2 (price): The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.
Footnote F3 (shares): The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Filed

Filer

Relationship

Market value

Notice

Sep 23, 2026

SALVATORE PRIVITERA

Officer

4,519

$271K

View on EDGAR

Sep 11, 2026

GROVES REGINA E

Director

5,313

$285K

Member	Type	Traded	Disclosed	Value range	Owner	Days to disclose	Filing
Gilbert Ray Cisneros, Jr.Democrat, CA-31	Sale (partial)

Member

Type

Traded

Disclosed

Value range

Owner

Days to disclose

Filing

Gilbert Ray Cisneros, Jr.Democrat, CA-31

Sale (partial)